Sandbox: Cardiogenic Shock: Difference between revisions
Arzu Kalayci (talk | contribs) |
Arzu Kalayci (talk | contribs) |
||
Line 64: | Line 64: | ||
{| class="wikitable" style="width: 90%; text-align: justify;" | {| class="wikitable" style="width: 90%; text-align: justify;" | ||
! style="width: | ! style="width:24%" | '''Monitoring Parameter''' | ||
! style="width: | ! style="width:21%" | '''Frequency''' | ||
! style="width:55%" | '''Comment/Rationale''' | ! style="width:55%" | '''Comment/Rationale''' | ||
|- | |- |
Revision as of 14:39, 3 November 2017
Template:Cardiogenic Shock - 2017
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1],Associate Editor(s)-in-Chief: Arzu Kalayci, M.D. [2]
AHA SCIENTIFIC STATEMENT - 2017
Contemporary Management of Cariogenic Shock
Pragmatic and Clinical Trial Definitions of Cardiogenic Shock
Clinical Definition | SHOCK Trial | IABP-SHOCK II | ESC HF Guidelines |
---|---|---|---|
Cardiac disorder that results in both clinical and biochemical evidence of tissue hypoperfusion | Clinical criteria:
SBP <90 mmHg for ≥30 min OR Support to maintain SBP ≥90 mmHg AND End-organ hypoperfusion (urine output <30 mL/h or cool extremities) Hemodynamic criteria: CI of ≤2.2 L·min−1·m−2 AND PCWP ≥15 mmHg |
Clinical criteria:
SBP <90 mmHg for ≥30 min OR Catecholamines to maintain SBP >90 mmHg AND Clinical pulmonary congestion AND Impaired end-organ perfusion (altered mental status, cold/clammy skin and extremities, urine output <30 mL/h, or lactate >2.0 mmol/L) |
SBP <90 mmHg with adequate volume and clinical or laboratory signs of hypoperfusion
Clinical hypoperfusion: Cold extremities, oliguria, mental confusion, dizziness, narrow pulse pressure Laboratory hypoperfusion: Metabolic acidosis, elevated serum lactate, elevated serum creatinine |
CI indicates cardiac index; CS, cardiogenic shock; ESC, European Society of Cardiology; HF, heart failure; IABP-SHOCK II, Intraaortic Balloon Pump in Cardiogenic Shock II; LV, left ventricular; MI, myocardial infarction; PCWP, pulmonary capillary wedge pressure; SBP, systolic blood pressure; and SHOCK, Should We Emergently Revascularize Occluded Coronaries for Cariogenic Shock |
Potential Hemodynamic Presentations of Cardiogenic Shock
Volume Status | |||
Peripheral Circulation | Cold | Classic Cardiogenic Shock or Mixed Shock (↓Cl; ↑SVRI; ↑PCWP) | Euvolemic Cardiogenic Shock (↓Cl; ↑SVRI;↔PCWP) |
Warm | Vasodilatory Cardiogenic Shock or Mixed Shock (↓Cl; ↓/↔SVRI;↑PCWP) | Vasodilatory Shock (Not Cardiogenic Shock) (↑Cl; ↓SVRI; ↓PCWP) | |
CI indicates cardiac index; PCWP, pulmonary capillary wedge pressure; and SVRI, systemic vascular resistance index. |
Considerations for Initial Critical Care Monitoring in Patients With Cardiogenic Shock
Monitoring Parameter | Frequency | Comment/Rationale |
---|---|---|
Noninvasive Monitoring | ||
Telemetry, pulse oximetry, respiratory rate | Continuous | High incidence of arrhythmias, ventilator failure, and pulmonary edema |
Critical care unit monitoring | 1:1 Nurse-to-patient ratio | High incidence of hemodynamic deterioration and multisystem organ failure |
Invasive monitoring | ||
Arterial BP monitoring | Continuous | Consider continuing until vasoactive medications have been discontinued for 12–24 h |
CVP | Continuous | A central line is required for delivery of vasoactive medications; single-point-in-time CVP measurements may be unreliable measures of uid status, but longitudinal CVP trends may provide information on trends in fluid status |
Central venous oxygen saturation | Every 4 h | Trends in central venous oxygen saturation in patients with a central line can be used to help monitor trends in cardiac output |
Urine output | Every hour | Urine output and serum creatinine monitoring are markers of renal perfusion and acute kidney injury |
PAC or noninvasive cardiac output monitor | Selected use | Consider using early in the treatment course in patients not responsive to initial therapy or in cases of diagnostic or therapeutic uncertainty |
Laboratory Investigations | ||
Complete blood counts | Every 12–24 h | Consider more frequently in patients with CS with, or at high risk for, bleeding |
Serum electrolytes | Every 6–12 h | Frequency should be tailored to risks or presence of renal failure and electrolyte dycrasias |
Serum creatinine | Every 12–24 h | Urine output and serum creatinine monitoring are markers of renal perfusion and acute kidney injury |
Liver function tests | Daily | Monitoring for congestive hepatopathy and hypo perfusion |
Lactate | Every 1–4 h | Lactate clearance is a marker of resolving end-organ hypoperfusion, and lack of clearance is associated with a higher risk of mortality |
Coagulation laboratories | Every 4–6 h for those on anticoagulants until therapeutically stable, every 24 h if patient is not on anticoagulants | Altered drug elimination and frequent use of mechanical support devices often necessitate antithrombotic monitoring |
BP indicates blood pressure; CS, cardiogenic shock; CVP, central venous pressure; and PAC, pulmonary artery catheter. |